Managing multiple myeloma
- PMID: 34462295
- PMCID: PMC8432308
- DOI: 10.1503/cmaj.202824
Managing multiple myeloma
Conflict of interest statement
Competing interests: Irwindeep Sandhu reports speaker fees from, and board participation with, Celgene/BMS, Amgen, Gilead/Kite, Janssen, Takeda, Beigene, Novartis and Pfizer, as well as stock with IllumiSonics Inc. No other competing interests were declared.
Comment in
-
Prise en charge du myélome multiple.CMAJ. 2021 Oct 25;193(42):E1647-E1648. doi: 10.1503/cmaj.202824-f. CMAJ. 2021. PMID: 34697104 Free PMC article. French. No abstract available.
References
-
- Tsang M, Le M, Ghazawi FM, et al. . Multiple myeloma epidemiology and patient geographic distribution in Canada: a population study. Cancer 2019;125:2435–44. - PubMed
-
- Mikhael J, Ismaila N, Cheung MC, et al. . Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline. [published erratum in: J Clin Oncol 2020;38:2469]. J Clin Oncol 2019;37: 1228–63. - PubMed
-
- Anderson K, Ismaila N, Flynn PJ, et al. . Role of bone-modifying agents in multiple myeloma: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2018;36:812–8. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical